Clariant, SICPA launch security solution for medical devices

Clariant, a leading speciality chemicals company, and SICPA SA, provider of global security solutions, have joined hands to develop and launch a robust in -product protection solution for plastic medical devices.
The solution, Plastiward, will help tackle counterfeit medical devices.
"We have teamed up with SICPA SA to develop and launch Plastiward, a robust integrated protection for plastic pharmaceutical packaging for medical devices. The combined expertise will provide unique 'end-to-end' solution," Clariant said in a statement here.
According to the World Health Organisation, more than 8 per cent of the medical devices in circulation are counterfeit. Interpol estimates USD 75 billion counterfeit pharmaceuticals enter the market every year.

Clearly, bogus medical devices pose a significant liability to their manufacturers and a risk of injury, permanent disability, or even death to both patients and healthcare providers, the statement said.
The mission of safe access to treatments remains a challenge to medical devices and pharmaceutical firms despite investments in fighting fakes. As it is well accepted that layers of security features are necessary, the unique features of Plastiward can help reinforce this approach, it said.
"Plastiward offers medical-device and pharmaceutical- packaging companies a two-in-one approach. It combines Clariant's track record in developing polymer compounds and masterbatches tailored to the unique requirements of clients in those sectors with SICPA's expertise in protecting brands and products," said Clariant Head of Global Segment Healthcare Polymer Solutions Steve Duckworth.